Robert Zurier is a Rheumatology/Immunology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
55 Lake Ave N
Department Of Rheumatology
Worcester, MA 016550002
Telephone
508-856-6246Registry record last updated 23 Mar 2009.
Clinical trials
- JBT-101 in Systemic Lupus Erythematosus (SLE)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Treatment of Rheumatoid Arthritis With Marine and Botanical Oils
Sponsor: National Center for Complementary and Integrative Health (NCCIH)
- Study of Gammalinolenic Acid for Juvenile Rheumatoid Arthritis
Sponsor: FDA Office of Orphan Products Development
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Genitourinary & hormones
63.3%beta3-Adrenergic Agonist63.3%Myrbetriq100%Part D<11 patientsNervous system
36.7%SSRI36.7%Sertraline Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
6 NIH research awards on record, funded 1990–2012 per NIH RePORTER. The latest:
- Development of a Nonpsychotropic Cannabinoid Agonist for the Treatment of Sclerod
Jb Therapeutics, Inc.
FY2012$294,381R43AR063175 - Treatment of Rheumatoid Arthritis-Marine/Botanical Oils
Univ of Massachusetts Med Sch Worcester
FY2008$13,490R01AT000309 - Treatment of Rheumatoid Arthritis-Marine/Botanical Oils
Univ of Massachusetts Med Sch Worcester
FY2006$712,334R01AT000309
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”